China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback